Pituitary apoplexy is a rare endocrine emergency. The purpose of this study is to characterize physiological changes involved in pituitary apoplexy, especially during the acute phase.
A Cushing’s disease patient experienced corticotroph releasing hormone (CRH)-induced pituitary apoplexy during inferior petrosal sinus sampling (IPSS). The IPSS blood samples from the Cushing’s disease patient were retrospectively analyzed for cytokine markers. For comparison, we also analyzed cytokine markers in blood samples from two pituitary ACTH-secreting microadenoma patients and one patient with an ectopic ACTH-secreting tumor.
Acute elevation of interleukin 6 (IL-6) and matrix metalloproteinase 9 (MMP9) was observed in the IPSS blood sample on the apoplectic hemorrhagic site of the tumor. In contrast, such a change was not observed in the blood samples from the contralateral side of the apoplexy patient and in other IPSS samples from two non-apoplexy Cushing’s disease patient and a patient with ectopic Cushing’s syndrome.
IL-6 and MMP9 may be involved in the acute process of pituitary apoplexy in Cushing’s disease.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Briet C et al (2015) Pituitary apoplexy. Endocr Rev 36(6):622–645
Baldeweg SE et al (2016) Society for Endocrinology Endocrine Emergency Guidance: emergency management of pituitary apoplexy in adult patients. Endocr Connect 5(5):G12–G15
Capatina C et al (2015) Management of endocrine disease: pituitary tumour apoplexy. Eur J Endocrinol 172(5):R179–R190
Zhang F et al (2009) Manifestation, management and outcome of subclinical pituitary adenoma apoplexy. J Clin Neurosci 16(10):1273–1275
Otsuka F et al (1998) Pituitary apoplexy induced by a combined anterior pituitary test: case report and literature review. Endocr J 45(3):393–398
Kaltsas GA et al (1999) A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing’s disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 84(2):487–492
Jehle S et al (2008) Selective use of bilateral inferior petrosal sinus sampling in patients with adrenocorticotropin-dependent Cushing’s syndrome prior to transsphenoidal surgery. J Clin Endocrinol Metab 93(12):4624–4632
Gupta P, Dutta P (2018) Landscape of molecular events in pituitary apoplexy. Front Endocrinol 9:107
Xiao Z et al (2011) Hypoxia induces hemorrhagic transformation in pituitary adenomas via the HIF-1α signaling pathway. Oncol Rep 26(6):1457–1464
Xiao Z et al (2011) TNF-α-induced VEGF and MMP-9 expression promotes hemorrhagic transformation in pituitary adenomas. Int J Mol Sci 12(6):4165–4179
Ishikawa H et al (2001) Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab 86(2):867–874
Jayaraman T et al (2008) TNF-alpha-mediated inflammation in cerebral aneurysms: a potential link to growth and rupture. Vasc Health Risk Manag 4(4):805–817
Kim K, Yoshida D, Teramoto A (2005) Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in pituitary adenomas. Endocr Pathol 16(2):115–121
Cristina C, Luque GM (2014) Angiogenesis in pituitary adenomas: human studies and new mutant mouse models. Int J Endocrinol 2014:608497
Jarzembowski J, Lloyd R, McKeever P (2007) Type IV collagen immunostaining is a simple, reliable diagnostic tool for distinguishing between adenomatous and normal pituitary glands. Arch Pathol Lab Med 131(6):931–935
Kawamoto H et al (1996) Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir (Wien) 138(4):390–395
Lambertsen KL, Biber K, Finsen B (2012) Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 32(9):1677–1698
Tsuge M et al (2010) Increase of tumor necrosis factor-alpha in the blood induces early activation of matrix metalloproteinase-9 in the brain. Microbiol Immunol 54(7):417–424
Spinale FG, Villarreal F (2014) Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol 90(1):7–15
Zhang X, Shen YH, LeMaire SA (2009) Thoracic aortic dissection: are matrix metalloproteinases involved? Vascular 17(3):147–157
Ryuto M et al (1996) Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 271(45):28220–28228
Li G et al (2014) The relationship between serum hypoxia-inducible factor 1α and coronary artery calcification in asymptomatic type 2 diabetic patients. Cardiovasc Diabetol 13:52–52
Shao Y et al (2016) Levels of serum 25(OH)VD3, HIF-1α, VEGF, vWf, and IGF-1 and their correlation in type 2 diabetes patients with different urine albumin creatinine ratio. J Diabetes Res 2016:1925424
Rong B et al (2018) Correlation of serum levels of HIF-1α and IL-19 with the disease progression of COPD: a retrospective study. Int J Chron Obstruct Pulmon Dis 13:3791–3803
He J et al (2016) The relationship between the preoperative plasma level of HIF-1α and clinic pathological features, prognosis in non-small cell lung cancer. Sci Rep 6:20586
Loriaux DL (2017) Diagnosis and differential diagnosis of Cushing’s syndrome. N Engl J Med 376(15):1451–1459
Gandhi CD et al (2008) Neurologic complications of inferior petrosal sinus sampling. Am J Neuroradiol 29(4):760–765
Elshal MF, McCoy JP (2006) Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods (San Diego, Calif.) 38(4):317–323
Rotman-Pikielny P, Patronas N, Papanicolaou DA (2003) Pituitary apoplexy induced by corticotrophin-releasing hormone in a patient with Cushing’s disease. Clin Endocrinol 58(5):545–549
Chen R et al (1993) Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 90(19):8967–8971
Kameda H et al (2019) Proton sensitivity of corticotropin-releasing hormone receptor 1 signaling to proopiomelanocortin in male mice. Endocrinology 160(2):276–291
Venihaki M et al (2001) Corticotropin-releasing hormone regulates IL-6 expression during inflammation. J Clin Invest 108(8):1159–1166
Turnbull AV et al (1999) CRF type I receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation. Endocrinology 140(2):1013–1017
Kothari P et al (2014) IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages. J Immunol (Baltimore, Md.: 1950) 192(1):349–357
Kanbe N et al (1999) Human mast cells produce matrix metalloproteinase 9. Eur J Immunol 29(8):2645–2649
Taniguchi-Ponciano K et al (2020) Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors. Sci Rep 10(1):19373
Turner HE et al (2000) Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab 85(8):2931–2935
Paoletta A et al (2011) Intrapituitary cytokines in Cushing’s disease: do they play a role? Pituitary 14(3):236–241
Watanobe H et al (1998) Measurement of cytokines in the cavernous sinus plasma from patients with Cushing’s disease. Neuropeptides 32(2):119–123
Sothern RB et al (1995) Circadian characteristics of circulating interleukin-6 in men. J Allergy Clin Immunol 95(5 Pt 1):1029–1035
This study is supported by grants from the University of Minnesota (UMF0011528 to TA, AHC Grant-in-Aid 212588 to TA) and a grant from the NIH (R01AR064195 to YK). We are grateful to Dr. Yasumasa Iwasaki for critical reading, to Cailin McMahon and Mathew Pappas for editorial assistance, to Justin Wang for his excellent technical assistance and to Michael Ehrhardt at the Cytokine reference laboratory for blood sample assays.
Conflict of interest
The authors have no multiplicity of interest to disclose.
Study protocols were approved by the University of Minnesota Institutional Review Board (protocol #00005168). Informed consent was obtained from patients over 18 years of age, who were diagnosed with Cushing’s syndrome and underwent the IPSS procedure.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Araki, T., Sangtian, J., Ruanpeng, D. et al. Acute elevation of interleukin 6 and matrix metalloproteinase 9 during the onset of pituitary apoplexy in Cushing’s disease. Pituitary (2021). https://doi.org/10.1007/s11102-021-01157-0
- Pituitary apoplexy
- Cushing's disease